{"id":3348,"date":"2025-09-04T17:13:25","date_gmt":"2025-09-04T21:13:25","guid":{"rendered":"http:\/\/www.arraysbank.com\/blog\/?p=3348"},"modified":"2025-09-04T17:46:42","modified_gmt":"2025-09-04T21:46:42","slug":"metastatic-castration-resistant-prostate-cancer-tissue-microarray","status":"publish","type":"post","link":"https:\/\/www.arraysbank.com\/blog\/metastatic-castration-resistant-prostate-cancer-tissue-microarray\/","title":{"rendered":"Metastatic Castration-Resistant Prostate Carcinoma Tissue Microarray | ArraysBank"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

Explore a 100-case mCRPC tissue microarray<\/a> with Gleason score, grade, medication, metastatic sites & IHC results\u2014supporting prostate cancer<\/a> research.<\/h3>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n
\n
\n
\n

Introduction<\/h2>\n

Metastatic castration-resistant prostate carcinoma (mCRPC) remains one of the most challenging stages of prostate cancer, representing disease progression despite androgen deprivation therapy. To accelerate research in oncology, reliable and well-characterized human samples are critical. ArraysBank now offers a tissue microarray (TMA)<\/a> of 100 mCRPC adenocarcinoma cases<\/strong>, designed to provide investigators with standardized material for biomarker validation, therapeutic studies, and translational research.<\/p>\n

\n

What This Tissue Microarray Includes<\/h2>\n

The mCRPC tissue microarray<\/strong> is carefully constructed to maximize research value and reproducibility. Each case contributes a single representative core, enabling high-throughput screening and comparison.<\/p>\n

Key features include:<\/p>\n

    \n
  • \n

    100 cases of metastatic prostate adenocarcinoma<\/strong><\/p>\n<\/li>\n

  • \n

    Single core per case<\/strong> to streamline experimental consistency<\/p>\n<\/li>\n

  • \n

    Detailed pathological information<\/strong> for each case:<\/p>\n

      \n
    • \n

      Gleason Score & Gleason Grade<\/strong><\/p>\n<\/li>\n

    • \n

      Preoperative medication history<\/strong> (including androgen deprivation or other neoadjuvant therapies)<\/p>\n<\/li>\n

    • \n

      Metastatic location<\/strong> (bone, lymph node, liver, lung, etc.)<\/p>\n<\/li>\n

    • \n

      Immunohistochemical (IHC) results<\/strong> for key biomarkers<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

      This comprehensive dataset ensures that scientists can correlate molecular findings with clinical outcomes and pathological features.<\/p>\n

      \n

      Why Use a Tissue Microarray for mCRPC Research?<\/h2>\n

      The tissue array format<\/strong> offers unique advantages over individual slides or blocks:<\/p>\n

        \n
      • \n

        Efficiency<\/strong> \u2013 Hundreds of cases can be studied in parallel on a single slide.<\/p>\n<\/li>\n

      • \n

        Comparability<\/strong> \u2013 Uniform processing reduces variability between samples.<\/p>\n<\/li>\n

      • \n

        Clinical Relevance<\/strong> \u2013 Each core is annotated with critical clinical and pathological parameters, making results more translational.<\/p>\n<\/li>\n

      • \n

        Cost-effectiveness<\/strong> \u2013 Researchers save time and resources compared to sourcing individual specimens.<\/p>\n<\/li>\n<\/ul>\n

        \n

        Applications in Prostate Cancer Research<\/h2>\n

        The mCRPC tissue microarray<\/strong> is suitable for multiple research applications, including:<\/p>\n

          \n
        • \n

          Biomarker discovery and validation<\/strong> \u2013 Linking IHC results to Gleason Scores and metastatic sites.<\/p>\n<\/li>\n

        • \n

          Drug development<\/strong> \u2013 Assessing therapeutic targets in castration-resistant prostate cancer tissue.<\/p>\n<\/li>\n

        • \n

          Precision oncology<\/strong> \u2013 Studying patient variability based on medication history and metastatic progression.<\/p>\n<\/li>\n

        • \n

          Educational use<\/strong> \u2013 Supporting medical training in pathology and oncology.<\/p>\n<\/li>\n<\/ul>\n

          \n

          Quality Assurance at ArraysBank<\/h2>\n

          All tissue microarrays at ArraysBank are prepared under strict quality standards. Each block undergoes:<\/p>\n

            \n
          • \n

            Ethical and IRB-compliant sourcing<\/strong><\/p>\n<\/li>\n

          • \n

            H&E staining and pathologist verification<\/strong><\/p>\n<\/li>\n

          • \n

            Multi-layer quality control<\/strong> for tissue integrity and annotation accuracy<\/p>\n<\/li>\n

          • \n

            Secure storage and shipping protocols<\/strong> to preserve antigenicity<\/p>\n<\/li>\n<\/ul>\n

            \n

            Conclusion<\/h2>\n

            The mCRPC tissue microarray with 100 adenocarcinoma cases<\/strong> provides an unparalleled tool for prostate cancer researchers. With detailed Gleason scoring, treatment history, metastatic site data, and immunohistochemistry results, this product enables deeper understanding of disease mechanisms and supports the development of new therapeutic strategies.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

            \n
            <\/div>\n<\/div>\n
            <\/div>\n
            \n
            \n
            \n
            \n
            \n
            \"Metastatic
            Metastatic Castration-Resistant Prostate Cancer Tissue Microarray<\/figcaption><\/figure>\n
            <\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

            Explore a 100-case mCRPC tissue microarray with Gleason score, grade, medication, metastatic sites & IHC results\u2014supporting prostate cancer research. Introduction Metastatic castration-resistant prostate carcinoma (mCRPC) remains one of the most challenging stages of prostate cancer, representing disease progression despite androgen deprivation therapy. To accelerate research in oncology, reliable and well-characterized human samples are critical. ArraysBank […]<\/p>\n","protected":false},"author":1,"featured_media":3350,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-3348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tissue-microarray"],"blocksy_meta":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts\/3348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/comments?post=3348"}],"version-history":[{"count":9,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts\/3348\/revisions"}],"predecessor-version":[{"id":3383,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts\/3348\/revisions\/3383"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/media\/3350"}],"wp:attachment":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/media?parent=3348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/categories?post=3348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/tags?post=3348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}